Literature DB >> 32078063

A negative association between urinary iodine concentration and the prevalence of hyperuricemia and gout: a cross-sectional and population-based study in Mainland China.

Xixuan Lu1,2, Xiaoguang Shi3,1, Yanbo Li4, Haiyi Chi5, Eryuan Liao6, Chao Liu7, Libin Liu8, Yongze Li3,1, Di Teng3,1, Xiaochun Teng3,1, Jianming Ba9, Bing Chen10, Jianling Du11, Lanjie He2, Xiaoyang Lai12, Guijun Qin13, Yingfen Qin14, Huibiao Quan15, Bingyin Shi16, Hui Sun17, Xulei Tang18, Nanwei Tong19, Guixia Wang20, Jin-An Zhang21, Youmin Wang22, Yuanming Xue23, Li Yan24, Jing Yang25, Lihui Yang26, Yongli Yao27, Zhen Ye28, Qiao Zhang29, Lihui Zhang30, Jun Zhu31, Mei Zhu32, Zhongyan Shan33,34, Weiping Teng35.   

Abstract

BACKGROUND AND AIMS: Iodine is one of the most important trace elements in the human body. It is not only the main component of thyroid hormones but also has extrathyroid biological functions. To date, there have been no large-scale epidemiological studies on the relationship between hyperuricemia and iodine intake, although both are closely related to health. A population-based epidemiological survey in China offers such an opportunity.
METHODS: This population-based cross-sectional study recruited 75,653 adults aged ≥ 18 years from 2015 to 2017 with a randomized, multistage, stratified sampling strategy. Serum uric acid levels and urinary iodine concentrations (UICs) were measured.
RESULTS: Stratified by UIC, the prevalence of hyperuricemia was 17.8%, 18.8%, 16.0% and 13.7% in the UIC < 100, 100-199, 200-299, and ≥ 300 μg/L groups, respectively; the prevalence of gout was 4.0%, 3.4%, 2.4% and 1.7%, respectively. The prevalence of gout decreased significantly as the UIC increased. The prevalence of hyperuricemia and gout were markedly higher in postmenopausal females than in the premenopausal population (hyperuricemia: 15.9% vs. 8.3%, X2 = 520.072, p < 0.001; gout: 3.6% vs. 1.3%, X2 = 219.889, p < 0.001), and the prevalence decreased as the UIC increased. Subjects in the more than adequate and excessive iodine groups had lower likelihoods of having hyperuricemia [aOR = 0.81 (95% CI 0.77-0.85), aOR = 0.68 (95% CI 0.64-0.72)] and lower odds of having gout than subjects in the adequate iodine (AI) group [aOR = 0.77 (95% CI 0.68-0.86), aOR = 0.59 (95% CI 0.51-0.68)].
CONCLUSIONS: UIC was inversely associated with the occurrence of hyperuricemia and gout. More in-depth research and prospective studies are needed to explore the molecular mechanisms and confirm the observed association.

Entities:  

Keywords:  Gout; Hyperuricemia; Iodine; Prevalence; Urinary iodine concentration

Mesh:

Substances:

Year:  2020        PMID: 32078063     DOI: 10.1007/s00394-020-02199-z

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  5 in total

1.  Methyl Gallate Improves Hyperuricemia Nephropathy Mice Through Inhibiting NLRP3 Pathway.

Authors:  Peng Liu; Wen Wang; Qiang Li; Xin Hu; Bingyong Xu; Chen Wu; Lijie Bai; Li Ping; Zhou Lan; Lvyi Chen
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

2.  Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study.

Authors:  Min Tao; Xiaoyan Ma; Xiaoling Pi; Yingfeng Shi; Lunxian Tang; Yan Hu; Hui Chen; Xun Zhou; Lin Du; Yongbin Chi; Shougang Zhuang; Na Liu
Journal:  BMJ Open       Date:  2021-09-16       Impact factor: 3.006

3.  Prevalence of hyperuricaemia in an Eastern Chinese population: a cross-sectional study.

Authors:  Bing Han; Ningjian Wang; Yi Chen; Qin Li; Chunfang Zhu; Yingchao Chen; Yingli Lu
Journal:  BMJ Open       Date:  2020-05-20       Impact factor: 2.692

4.  Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China.

Authors:  Jing Song; Chenye Jin; Zhongyan Shan; Weiping Teng; Jing Li
Journal:  J Transl Int Med       Date:  2022-07-07

Review 5.  Nanomaterials for the Diagnosis and Treatment of Inflammatory Arthritis.

Authors:  Seyedeh Maryam Hosseinikhah; Mahmood Barani; Abbas Rahdar; Henning Madry; Rabia Arshad; Vahideh Mohammadzadeh; Magali Cucchiarini
Journal:  Int J Mol Sci       Date:  2021-03-18       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.